Effects of thoracic radiotherapy timing and duration on progression-free survival in limited-stage small cell lung cancer.

The difference remained significant in patients receiving twice‐daily TRT (Figure 1 B: 15.57 vs 9.23 months P = .003), while marginally significant in those receiving once‐daily TRT (Figure 1 C: 12.13 vs 8.53, P = .050).

also in 26,082 other papers